A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)

NCT06857942 · clinicaltrials.gov ↗

PHASE4

Phase

RECRUITING

Status

200

Enrollment

INDUSTRY

Sponsor class

Conditions

Psoriasis
Overweight or Obesity

Interventions

DRUG: Tirzepatide

Sponsor

Eli Lilly and Company